CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA
SHANGHAI, March 1, 2019 /PRNewswire/ — CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug…